Skip to main content
Home
FULL MENU Close Menu
Home
Home

Neil Osterweil

News

COVID-19 infection conveys imperfect immunity in young adults

Author:
Neil Osterweil
Publish date: April 23, 2021

One in 10 Marine recruits with prior SARS-CoV-2 infections were reinfected during basic training.

  • Read More

News

Made-to-order TILs effective against metastatic melanoma

Author:
Neil Osterweil
Publish date: April 19, 2021

Cell therapy with tumor-infiltrating lymphocytes extracted from tumor tissue yielded responses in patients with...

  • Read More

News

New combo shows benefit even in patients with high-risk HCC

Author:
Neil Osterweil
Publish date: April 15, 2021

Updated data from the IMBRave150 trial show benefit for the combination of atezolizumab with bevacizumab even in...

  • Read More

News

New data dim hopes for ‘triumph of drug discovery’

Author:
Neil Osterweil
Publish date: April 14, 2021

Excitement over novel drugs that showed efficacy against KRAS mutations has been muted somewhat by new data...

  • Read More

News

Deadly brain tumor: Survival extended by oncolytic virus product

Author:
Neil Osterweil
Publish date: April 12, 2021

Improved survival was seen in a small trial in which a genetically engineered version of herpes simplex virus was infused directly into high-grade...

  • Read More

News

Presurgical nivo/chemo boosts pCR rates in NSCLC

Author:
Neil Osterweil
Publish date: April 12, 2021

For patients with resectable non–small cell lung cancer, adding immunotherapy to platinum-based chemotherapy...

  • Read More

News

Combo shows efficacy in platinum-resistant ovarian cancer

Author:
Neil Osterweil
Publish date: March 30, 2021

Ixabepilone plus bevacizumab improved outcomes, compared with ixabepilone alone.

  • Read More

News

Niraparib maintenance offers continued benefit in some with recurrent ovarian cancer

Author:
Neil Osterweil
Publish date: March 29, 2021

Benefits were seen in patients with germline BRCA mutations.

  • Read More

News

Biomarkers predict efficacy of DKN-01 in endometrial cancer

Author:
Neil Osterweil
Publish date: March 26, 2021

High levels of DKK1 expression and the presence of Wnt or PIK3CA activating mutations are associated with better outcomes.

  • Read More

News

Gynecologic cancer patients at risk of insurance loss, ‘catastrophic’ costs

Author:
Neil Osterweil
Publish date: March 25, 2021

The Affordable Care Act did not spare many gynecologic cancer patients from financial hardship.

  • Read More

News

Frail status may be better than age for predicting ovarian cancer outcomes

Author:
Neil Osterweil
Publish date: March 24, 2021

Older, fit patients may be better candidates for ovarian cancer surgery than younger, more frail patients, a...

  • Read More

News

Omidubicel improves on umbilical cord blood transplants

Author:
Neil Osterweil
Publish date: March 22, 2021

“Transplantation with omidubicel, compared to standard cord blood transplantation, results in faster...

  • Read More

News

Rucaparib extends PFS in BRCA-mutated ovarian cancer, with an exception

Author:
Neil Osterweil
Publish date: March 21, 2021

The PARP inhibitor was superior to chemotherapy, except in patients with BRCA reversion mutations.

  • Read More

News

GVHD prophylaxis: Similar outcomes with PTCy and ATG

Author:
Neil Osterweil
Publish date: March 19, 2021

There were no significant differences between posttransplant cyclophosphamide and antithymocyte globulin in...

  • Read More

News

Close joint health monitoring essential with new hemophilia therapies

Author:
Neil Osterweil
Publish date: March 12, 2021

Physical joint examinations and patient-reported outcomes only are not sufficient for detecting subclinical...

  • Read More

Pages

  • « first
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • last »

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2022 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close